Loading
Aerie Pharmaceuticals Inc Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by RUBINO RICHARD J, was filed 09 Sept 2019.
Aerie Pharmaceuticals Inc: what insiders have been doing
This page follows insider dealings at Aerie Pharmaceuticals Inc as filed with SEC (Form 4), a company from the Healthcare & Pharma sector based in Durham, United States. The group dates from 2005. Aerie Pharmaceuticals Inc has had no insider filing for more than a year; the last one goes back to 21 November 2022.
Our records for Aerie Pharmaceuticals Inc go back to 2016, with 34 purchases and 46 sales on the open market in total.
Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
320
Thresholds
n/a
Buy Volume
€24M
34 ops. · all time
Sell Volume
€51M
46 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2021FY ended December 2021 · cache
Income statement
RevenueUS$167.1M
Net income-US$64.4M-38.5% margin
Last declaration on 21 November 2022
Declarations320 total
1,996 shares@ US$15.2514.8% of flowCommon StockSEC:0001209191-22-058176:1
41,984 shares@ US$15.2589.0% of flowCommon StockSEC:0001209191-22-058189:0
280,244 shares@ US$15.2599.8% of flowCommon StockSEC:0001209191-22-058186:0
7,995 shares@ US$15.25100.0% of flowCommon StockSEC:0001209191-22-058188:0
11,495 shares@ US$15.25100.0% of flowCommon StockSEC:0001209191-22-058176:0
215,783 shares@ US$15.25100.0% of flowCommon StockSEC:0001209191-22-058154:0
16,095 shares@ US$15.25100.0% of flowCommon StockSEC:0001209191-22-058191:0
16,095 shares@ US$15.25100.0% of flowCommon StockSEC:0001209191-22-058165:0
53,585 shares@ US$15.2595.1% of flowCommon StockSEC:0001209191-22-058180:0
46,297 shares@ US$15.25100.0% of flowCommon StockSEC:0001209191-22-058183:0
18,585 shares@ US$15.2597.2% of flowCommon StockSEC:0001209191-22-058160:0
16,095 shares@ US$15.25100.0% of flowCommon StockSEC:0001209191-22-058172:0
179 shares@ US$15.221.0% of flowCommon StockSEC:0001209191-22-055670:0
265 shares@ US$11.571.1% of flowCommon StockSEC:0001209191-22-045975:0
771 shares@ US$11.571.0% of flowCommon StockSEC:0001209191-22-045976:0
266 shares@ US$8.360.8% of flowCommon StockSEC:0001209191-22-042043:0
11,276 shares0Common StockSEC:0001209191-22-041174:0
6,245 shares0Common StockSEC:0001209191-22-036386:0
6,245 shares0Common StockSEC:0001209191-22-036394:0
6,245 shares0Common StockSEC:0001209191-22-036389:0
6,245 shares0Common StockSEC:0001209191-22-036397:0
6,245 shares0Common StockSEC:0001209191-22-036354:0
6,245 shares0Common StockSEC:0001209191-22-036403:0
19,015 shares0Common StockSEC:0001209191-22-020656:0
46,297 shares0Common StockSEC:0001209191-22-020653:0
25 of 320 declarations
About Aerie Pharmaceuticals Inc
Aerie Pharmaceuticals Inc. was a U.S.-based ophthalmic pharmaceutical company listed on the NASDAQ in the United States under ticker AERI before being acquired by Alcon. The company was built around the discovery, development, and commercialization of therapies for eye diseases, with a particular emphasis on glaucoma and ocular hypertension. Its business model was rooted in specialty pharma economics: concentrated R&D, a narrowly focused therapeutic franchise, and a goal of converting differentiated science into approved products with meaningful commercial potential. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1337553/000162828021003345/aeri-20201231.htm?utm_source=openai))
Founded in the early 2010s, Aerie established its headquarters in Durham, North Carolina, placing it within one of the United States’ strongest life-science hubs. Over time, the company evolved from a development-stage ophthalmology name into a commercial-stage player. Its best-known products were Rhopressa (netarsudil ophthalmic solution), indicated to reduce elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension, and Rocklatan, a fixed-dose combination of netarsudil and latanoprost. These products became the core of Aerie’s glaucoma franchise and the main proof points of its technology platform. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1337553/000162828019013540/aeri10-qx93019.htm?utm_source=openai))
Read moreShow less
From a competitive standpoint, Aerie differentiated itself through a highly specialized ophthalmology focus and its ROCK-inhibitor-based mechanism of action. That specialization gave it a distinct position versus larger diversified pharma companies, which typically compete with broader portfolios but less targeted innovation. Aerie also pursued international expansion through licensing and commercialization partnerships, aiming to extend the reach of Rhopressa and Rocklatan beyond the U.S. while leveraging partners’ regional infrastructure. ([nasdaq.com](https://www.nasdaq.com/press-release/aerie-concludes-exclusive-license-agreement-with-santen-for-rhopressar-and-rocklatanr?utm_source=openai))
Beyond glaucoma, the company continued to invest in retinal-disease programs and sustained-release ophthalmic technologies, reflecting an ambition to build a broader eye-care pipeline. Even so, the defining recent corporate event was Alcon’s acquisition of Aerie, which underscored the strategic value of its commercial assets and R&D capabilities. For investors, Aerie is best understood as a specialist U.S. NASDAQ ophthalmology company that successfully translated niche innovation into a valuable franchise attractive to a global eye-care leader. ([alcon.com](https://www.alcon.com/media-release/alcon-acquire-aerie-pharmaceuticals-inc-enhancing-its-ophthalmic-pharmaceutical/?utm_source=openai))
